Literature DB >> 17037948

Polycystic ovary syndrome in adolescents: current and future treatment options.

George Mastorakos1, Irene Lambrinoudaki, George Creatsas.   

Abstract

Polycystic ovary syndrome (PCOS) is a very common disorder affecting 5-10% of women of reproductive age. The pivotal endocrine abnormalities of this syndrome are insulin resistance and ovarian and, to a lesser degree, adrenal hypersensitivity to hormonal stimulation. PCOS may manifest itself as early as the first decade of life by premature pubarche or menarche. Oligoamenorrhea in the first postpubarchal years, although very common, may be an early symptom of PCOS, especially in overweight girls with hirsutism or acne. Girls with low birth weight as well as a family history of diabetes mellitus or premature cardiovascular disease are at high risk for developing PCOS. Circulating bioavailable testosterone levels are usually elevated, while total testosterone may be normal due to low levels of sex hormone-binding globulin. The typical sonographic appearance of PCOS ovaries consists of high ovarian volume (>10 mL) and the presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter. However, this finding is not specific, since it may occur in >20% of healthy girls. The therapeutic goals in adolescents with PCOS is first to restore bodyweight and menses and to reduce the signs of hyperandrogenism. The reduction of bodyweight in this young age group may require the collaboration of the pediatrician, dietitian, and psychotherapist. The adolescent should be urged to adopt a healthy lifestyle with the aim to maintain a normal body mass index throughout adolescence and adult life. The choice of medical therapy depends on the clinical presentation. Oral contraceptives are a good option when acne and hirsutism are the principal complaints. Adolescents with isolated cycle irregularity may be placed on a cyclical progestin regimen to induce withdrawal bleeding. Metformin, by decreasing insulin resistance, alleviates many of the hormonal disturbances and restores menses in a considerable proportion of patients. It may be used alone or in combination with oral contraceptives. Independently of medical treatment, restoration and maintenance of bodyweight within normal range is of paramount importance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17037948     DOI: 10.2165/00148581-200608050-00004

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  85 in total

1.  Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.

Authors:  V L Armstrong; M I Wiggam; C N Ennis; B Sheridan; A I Traub; A B Atkinson; P M Bell
Journal:  QJM       Date:  2001-01

2.  Spironolactone as a single agent for long-term therapy of hirsute patients.

Authors:  P M Spritzer; K O Lisboa; S Mattiello; F Lhullier
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

3.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?

Authors:  D Cibula; M Hill; M Fanta; G Sindelka; J Zivny
Journal:  Hum Reprod       Date:  2001-05       Impact factor: 6.918

Review 5.  Polycystic ovary syndrome.

Authors:  V T Goudas; D A Dumesic
Journal:  Endocrinol Metab Clin North Am       Date:  1997-12       Impact factor: 4.741

6.  Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Authors:  Jean-Patrice Baillargeon; Daniela J Jakubowicz; Maria J Iuorno; Salomon Jakubowicz; John E Nestler
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

7.  Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.

Authors:  Miriam E Silfen; Michelle R Denburg; Alexandra M Manibo; Rogerio A Lobo; Richard Jaffe; Michel Ferin; Lenore S Levine; Sharon E Oberfield
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

8.  Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; D Trpković; L Balint-Perić
Journal:  Gynecol Endocrinol       Date:  1990-09       Impact factor: 2.260

9.  Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.

Authors:  Frank Lüdicke; Ulysse J Gaspard; Fabienne Demeyer; A Scheen; P Lefebvre
Journal:  Contraception       Date:  2002-12       Impact factor: 3.375

10.  A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.

Authors:  L Falsetti; D Dordoni; C Gastaldi; A Gastaldi
Journal:  Acta Eur Fertil       Date:  1986 Jan-Feb
View more
  10 in total

Review 1.  Identification and treatment of metabolic complications in pediatric obesity.

Authors:  Katie Larson Ode; Brigitte I Frohnert; Brandon M Nathan
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

2.  Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries.

Authors:  Antje Neubert; Yingfen Hsia; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Gerd Glaeske; Kari Furu; Helle Kieler; Mette Nørgaard; Antonio Clavenna; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess.

Authors:  Abel López-Bermejo; Marta Díaz; Erica Morán; Francis de Zegher; Lourdes Ibáñez
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 19.112

4.  Unlicensed use of metformin in children and adolescents in the UK.

Authors:  Yingfen Hsia; Dalia Dawoud; Alastair G Sutcliffe; Russell M Viner; Sanjay Kinra; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

5.  A comparison of anthropometric, metabolic, and reproductive characteristics of young adult women from opposite-sex and same-sex twin pairs.

Authors:  Pirkko Korsoff; Leonie H Bogl; Päivi Korhonen; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Richard J Rose; Risto Kaaja; Jaakko Kaprio
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-07       Impact factor: 5.555

Review 6.  Assisted Reproduction in Congenital Adrenal Hyperplasia.

Authors:  Anastasios Chatziaggelou; Evangelos G Sakkas; Raffaella Votino; Maria Papagianni; George Mastorakos
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-23       Impact factor: 5.555

7.  High fructose-enriched diet synergistically exacerbates endocrine but not metabolic changes in letrozole-induced polycystic ovarian syndrome in Wistar rats.

Authors:  Christopher O Akintayo; Anjola D Johnson; Olabimpe C Badejogbin; Kehinde S Olaniyi; Adesola A Oniyide; Isaac O Ajadi; Abdulfatai O Ojewale; Olorunsola I Adeyomoye; Adedeji B Kayode
Journal:  Heliyon       Date:  2021-01-05

8.  No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study.

Authors:  Hanne Strøm; Randi Selmer; Kåre I Birkeland; Henrik Schirmer; Tore Julsrud Berg; Anne Karen Jenum; Kristian Midthjell; Christian Berg; Lars Christian Stene
Journal:  BMC Public Health       Date:  2014-05-29       Impact factor: 3.295

Review 9.  Investigation of common risk factors between polycystic ovary syndrome and Alzheimer's disease: a narrative review.

Authors:  Nahid Sarahian; Hosna Sarvazad; Elham Sajadi; Nasrin Rahnejat; Narges Eskandari Roozbahani
Journal:  Reprod Health       Date:  2021-07-26       Impact factor: 3.223

10.  Hypertension Predisposition and Thermoregulation Delays in Adolescents with Polycystic Ovary Syndrome: A Pilot Study.

Authors:  Styliani Geronikolou; Flora Bacopoulou; Stavros Chryssanthopoulos; Dennis V Cokkinos; George P Chrousos
Journal:  Children (Basel)       Date:  2022-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.